Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
95% Confidence Interval
23%
Adverse Events
5%
After Surgery
12%
Aggregate Data
7%
Aggressive Prostate Cancer
9%
Androgen Deprivation Therapy
28%
ARAMIS
7%
Bacillus
7%
Bacillus Calmette
10%
Bladder Cancer
9%
Bone Metastasis
7%
Breast Cancer
12%
Cancer Detection
7%
Cancer Mortality
12%
Cancer-associated
6%
Cancer-specific Survival
7%
Cardiac Magnetic Resonance Imaging (cMRI)
9%
Castration-resistant Prostate Cancer
15%
Circulating Tumor DNA (ctDNA)
7%
Clear Cell Renal Cell Carcinoma (ccRCC)
7%
Comorbidity
6%
Confidence Interval
6%
COVID-19
7%
Darolutamide
11%
Diagnostic Support
6%
Elderly Patients
11%
Enzalutamide
7%
EPIC-26
12%
Europe
9%
European Randomized Study of Screening for Prostate Cancer
13%
Euthyroid
14%
Expanded Prostate Cancer Index Composite
11%
Finland
33%
Finnish Population
7%
Functional Outcome
7%
Genotype
6%
Hazard Ratio
13%
High Risk
6%
High-grade Prostate Cancer
12%
Hypothyroidism
13%
International Survey
8%
Laparoscopic Radical Prostatectomy
11%
Localized Prostate Cancer
9%
Long Non-coding RNA (LncRNA)
7%
Long-run Risk
8%
Lower Urinary Tract Symptoms
7%
Lymph Node Metastasis
6%
Lynch Syndrome
11%
Meta-analysis
5%
Metastasis
6%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
17%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
7%
Metastatic Prostate Cancer
12%
Multivariable
5%
Non-muscle Invasive Bladder Cancer (NMIBC)
8%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
7%
Odds Ratio
5%
Oncological Outcomes
11%
Overall Survival
20%
Patients with Prostate Cancer
11%
Penile Cancer
7%
Population-based
7%
Population-based Cohort
9%
Population-based Cohort Study
8%
Population-based Study
7%
Prognostic Factors
8%
Prostate
15%
Prostate Cancer
79%
Prostate Cancer Patients
19%
Prostate Cancer Risk
28%
Prostate Cancer Screening
25%
Prostate Radiotherapy
11%
Prostate-specific Antigen
12%
Prostate-specific Antigen Testing
6%
Prostatectomy
8%
Quality of Life
10%
Radical Prostatectomy
13%
Randomized Clinical Trial
8%
Randomized Controlled Trial
15%
Randomized Trial
7%
Register Study
7%
Renal Cancer
11%
Renal Cell Carcinoma
11%
Reoperation
7%
Reoperation Rate
7%
Retrospective Cohort Study
8%
Risk Factors
9%
Risk of Death
11%
Robot-assisted
7%
Statin Use
11%
Statins
7%
Surgical Outcomes
9%
Tampere
7%
Testosterone
7%
Three-dimensional (3D)
11%
Thyroid Hormones
11%
Tolerability
12%
Total Prostate-specific Antigen
8%
Tumor
10%
University Hospital
11%
Medicine and Dentistry
Acetylsalicylic Acid
5%
Androgen Deprivation Therapy
18%
Arm
5%
Asymptomatic Bacteriuria
7%
Big Data
7%
Biopsy Technique
8%
Bladder Cancer
8%
Breast Cancer
11%
Cancer Diagnosis
8%
Cancer Incidence
5%
Cancer Mortality
15%
Cancer Screening
8%
Cancer Survival
7%
Cancer Therapy
6%
Castration Resistant Prostate Cancer
5%
Clear Cell Renal Cell Carcinoma
14%
Cohort Analysis
14%
Comorbidity
6%
Conservative Treatment
5%
Continence
8%
Cystectomy
7%
Diseases
6%
Elderly Patient
11%
Genetics
5%
Hazard Ratio
8%
Health Care Cost
6%
Histology
5%
Hypothyroidism
9%
Immunotherapy
5%
Kidney Cancer
7%
Liotrix
11%
Lower Urinary Tract Symptom
7%
Magnetic Resonance Imaging
15%
Malignant Neoplasm
7%
Mammography
8%
Median Follow Up
6%
Neoplasm
8%
Nonsteroid Antiinflammatory Agent
7%
Overall Survival
16%
Prevalence
5%
Prognostic Factor
9%
Proportional Hazards Model
5%
Prostate Cancer
100%
Prostate Specific Antigen
14%
Prostatectomy
26%
Quality of Life
7%
Randomized Clinical Trials
7%
Randomized Controlled Trial
14%
Recurrent Disease
6%
Reoperation
9%
Retrospective Cohort Study
8%
Robot-Assisted Prostatectomy
8%
Screening of Prostate Cancer
7%
Specific Mortality
8%
Thyroid Gland
12%
Thyroid Hormone
11%
Tumor
8%
Urinary System
9%
Visual Analog Scale
5%